Drugs / Descartes-15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06304636 | Jun 2024 → Apr 2025 | plasma cell myeloma | Cartesian Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-13 | Cartesian Therapeutics | Results Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis cartesiantherapeutics.com ↗
In this trial, no significant adverse events or dose-limiting toxicities were reported in any participants (n=3). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-13 | Cartesian Therapeutics | Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis cartesiantherapeutics.com ↗ |
| 2024-09-03 | Cartesian Therapeutics | Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 cartesiantherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Descartes-15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06304636 ↗ |
| Modality | Cell therapy | “autologous BCMA-targeting RNA-engineered CAR T-cell therapy” NCT06304636 ↗ |